STOCK TITAN
  1. Home
  2. Sec-filings
  3. ZYME
  4. [SCHEDULE 13G/A] Zymeworks Inc. SEC Filing

[SCHEDULE 13G/A] Zymeworks Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock ZYME logo
Zymeworks

NASDAQ:ZYME

ZYME Rankings

#3658 Ranked by Market Cap
N/A Ranked by Dividends

ZYME Latest News

Jul 17, 2025
Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025
May 30, 2025
Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer
May 22, 2025
Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences
May 21, 2025
Zymeworks Announces Participation in Upcoming Investor Conferences
May 19, 2025
Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

ZYME Latest SEC Filings

Jun 27, 2025
[SCHEDULE 13D] Zymeworks Inc. SEC Filing
Jun 27, 2025
[Form 4] Zymeworks Inc. Insider Trading Activity
Jun 27, 2025
[8-K] Zymeworks Inc. Reports Material Event

ZYME Stock Data

1.02B
72.86M
0.08%
100.95%
5.7%
Biotechnology
Pharmaceutical Preparations
Link
United States
MIDDLETOWN